New hope for brain cancer? drug shows promise in early trial
NCT ID NCT02981940
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a drug called abemaciclib in people whose glioblastoma (a type of brain cancer) has come back. The drug is given before surgery to see how much reaches the tumor, and then to a separate group to see if it helps control the cancer for at least 6 months. The trial involves 45 participants and is no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abemaciclib (a targeted cancer drug taken as a capsule)
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma, a type of brain cancer that is hard to treat.
What could go wrong
This is a small, early-phase trial (45 participants) and results may not apply to all patients. The drug may not effectively control tumor growth or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021, United States
-
UT, M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143-0372, United States